Clinical Trial

The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, single-arm, Phase II investigator-initiated trial of hypofractionated radiotherapy combined with PD-L1 inhibitor sequential GM-CSF and thymopentin for treatment of elderly patients with advanced solid tumors, when the HER-2 positive patients are treated with extra antibody-drug conjugate.
Trial Details
NCT Number NCT06112041
Lead Sponsor Second Affiliated Hospital of Soochow University
Conditions Carcinoma, Solid Tumor
Enrollment 29 participants
Start Date 2023-10-25
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-01